Riedijk Martiene, van den Bergh Walter M, van Vliet Maarten, Kusadasi Nuray, Span Lambert R F, Tuinman Pieter R, Arbous M Sesmu, Müller Marcella C A
Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Department of Critical Care, University Medical Center, University of Groningen, Groningen, The Netherlands.
Crit Care Resusc. 2015 Dec;17(4):268-73.
Patients with haematological malignancies are at risk of concomitant critical neurological events warranting intensive care unit admission. We aimed to examine the characteristics and outcomes of this patient population, as more knowledge could facilitate decision making on ICU admission and treatment.
DESIGN, SETTING AND PARTICIPANTS: A retrospective cohort study of 68 patients in adult ICUs of six Dutch university hospitals between 2003 and 2011.
The median Acute Physiology and Chronic Health Evaluation (APACHE) II score was 23 (IQR, 16-27), and 77% of patients needed mechanical ventilation within the first 24 hours of admission. Forty percent of patients had received an allogeneic stem cell transplantation, and 22% were neutropenic on admission. The most frequent underlying haematological condition was non-Hodgkin lymphoma (27%). Seizures were the most common neurological event for ICU admission (29%). The median ICU length of stay was 5 days (IQR, 1-13 days). ICU mortality (28%), hospital mortality (37%) and 3-month mortality (50%) were comparable with other studies of ICU patients with haematological malignancies. Factors associated with 3-month survival were baseline platelet count (113×10(9)/L in survivors v 39×10(9)/L in non-survivors, P<0.01) and APACHE II score (20 in survivors v 25 in non-survivors, P=0.02).
Patients with a history of haematological malignancy presenting with a critical neurological event have comparable survival rates with other patients with a haematologic malignancy admitted to the ICU. Our findings suggest that restrictions in ICU care are not justified for this patient population.
血液系统恶性肿瘤患者有发生危及生命的神经系统事件并需要入住重症监护病房的风险。我们旨在研究这一患者群体的特征和预后,因为更多的了解有助于做出关于入住重症监护病房及治疗的决策。
设计、地点和参与者:一项对2003年至2011年间荷兰六所大学医院成人重症监护病房中68例患者的回顾性队列研究。
急性生理与慢性健康状况评估(APACHE)II评分中位数为23(四分位间距,16 - 27),77%的患者在入院后24小时内需要机械通气。40%的患者接受过异基因干细胞移植,22%的患者入院时中性粒细胞减少。最常见的潜在血液系统疾病是非霍奇金淋巴瘤(27%)。癫痫发作是入住重症监护病房最常见的神经系统事件(29%)。重症监护病房住院时间中位数为5天(四分位间距,1 - 13天)。重症监护病房死亡率(28%)、医院死亡率(37%)和3个月死亡率(50%)与其他血液系统恶性肿瘤重症监护病房患者的研究结果相当。与3个月生存率相关的因素是基线血小板计数(存活者为113×10⁹/L,非存活者为39×10⁹/L,P<0.01)和APACHE II评分(存活者为20,非存活者为25,P = 0.02)。
有血液系统恶性肿瘤病史且出现危及生命的神经系统事件的患者与入住重症监护病房的其他血液系统恶性肿瘤患者生存率相当。我们的研究结果表明,对这一患者群体限制重症监护病房护理是不合理的。